These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 27423962)

  • 1. Evaluating the clinical relevance of a cognitive composite outcome measure: An analysis of 1414 participants from the 5-year GuidAge Alzheimer's prevention trial.
    Coley N; Gallini A; Ousset PJ; Vellas B; Andrieu S;
    Alzheimers Dement; 2016 Dec; 12(12):1216-1225. PubMed ID: 27423962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma p-tau181 as an outcome and predictor of multidomain intervention effects: a secondary analysis of a randomised, controlled, dementia prevention trial.
    Coley N; Zetterberg H; Cantet C; Guyonnet S; Ashton NJ; Vellas B; Blennow K; Andrieu S;
    Lancet Healthy Longev; 2024 Feb; 5(2):e120-e130. PubMed ID: 38310892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tracking early decline in cognitive function in older individuals at risk for Alzheimer disease dementia: the Alzheimer's Disease Cooperative Study Cognitive Function Instrument.
    Amariglio RE; Donohue MC; Marshall GA; Rentz DM; Salmon DP; Ferris SH; Karantzoulis S; Aisen PS; Sperling RA;
    JAMA Neurol; 2015 Apr; 72(4):446-54. PubMed ID: 25706191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of Alzheimer's Disease Dementia: Data from the GuidAge Prevention Trial.
    Di Stefano F; Epelbaum S; Coley N; Cantet C; Ousset PJ; Hampel H; Bakardjian H; Lista S; Vellas B; Dubois B; Andrieu S;
    J Alzheimers Dis; 2015; 48(3):793-804. PubMed ID: 26402073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Alzheimer's Prevention Initiative Composite Cognitive Test: a practical measure for tracking cognitive decline in preclinical Alzheimer's disease.
    Langbaum JB; Ellison NN; Caputo A; Thomas RG; Langlois C; Riviere ME; Graf A; Lopez Lopez C; Reiman EM; Tariot PN; Hendrix SB
    Alzheimers Res Ther; 2020 May; 12(1):66. PubMed ID: 32460855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer's disease.
    Langbaum JB; Hendrix SB; Ayutyanont N; Chen K; Fleisher AS; Shah RC; Barnes LL; Bennett DA; Tariot PN; Reiman EM
    Alzheimers Dement; 2014 Nov; 10(6):666-74. PubMed ID: 24751827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cognitive decline as an outcome and marker of progression toward dementia, in early preventive trials.
    Mura T; Coley N; Amieva H; Berr C; Gabelle A; Ousset PJ; Vellas B; Andrieu S;
    Alzheimers Dement; 2022 Apr; 18(4):676-687. PubMed ID: 34482607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment.
    Fleisher AS; Sowell BB; Taylor C; Gamst AC; Petersen RC; Thal LJ;
    Neurology; 2007 May; 68(19):1588-95. PubMed ID: 17287448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progression of Alzheimer's disease during a three-year follow-up using the CERAD-NB total score: Kuopio ALSOVA study.
    Hallikainen I; Hänninen T; Fraunberg M; Hongisto K; Välimäki T; Hiltunen A; Karppi P; Sivenius J; Soininen H; Koivisto AM;
    Int Psychogeriatr; 2013 Aug; 25(8):1335-44. PubMed ID: 23676340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
    Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
    J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychometric evaluation of ADAS-Cog and NTB for measuring drug response.
    Karin A; Hannesdottir K; Jaeger J; Annas P; Segerdahl M; Karlsson P; Sjögren N; von Rosen T; Miller F
    Acta Neurol Scand; 2014 Feb; 129(2):114-22. PubMed ID: 23763450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Validation of the Short Cognitive Battery (B2C). Value in screening for Alzheimer's disease and depressive disorders in psychiatric practice].
    Robert PH; Schuck S; Dubois B; Lépine JP; Gallarda T; Olié JP; Goni S; Troy S
    Encephale; 2003; 29(3 Pt 1):266-72. PubMed ID: 12876552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a straightforward and sensitive scale for MCI and early AD clinical trials.
    Huang Y; Ito K; Billing CB; Anziano RJ;
    Alzheimers Dement; 2015 Apr; 11(4):404-14. PubMed ID: 25022537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mild cognitive impairment in Parkinson's disease versus Alzheimer's disease.
    Besser LM; Litvan I; Monsell SE; Mock C; Weintraub S; Zhou XH; Kukull W
    Parkinsonism Relat Disord; 2016 Jun; 27():54-60. PubMed ID: 27089852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.
    Lannfelt L; Blennow K; Zetterberg H; Batsman S; Ames D; Harrison J; Masters CL; Targum S; Bush AI; Murdoch R; Wilson J; Ritchie CW;
    Lancet Neurol; 2008 Sep; 7(9):779-86. PubMed ID: 18672400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trajectory of the MAPT-PACC-Preclinical Alzheimer Cognitive Composite in the Placebo Group of a Randomized Control Trial: Results from the MAPT Study: Lessons for Further Trials.
    Chhetri JK; de Souto Barreto P; Cantet C; Cesari M; Coley N; Andrieu S; Vellas B
    J Prev Alzheimers Dis; 2018; 5(1):31-35. PubMed ID: 29405230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment.
    Fleisher AS; Sun S; Taylor C; Ward CP; Gamst AC; Petersen RC; Jack CR; Aisen PS; Thal LJ
    Neurology; 2008 Jan; 70(3):191-9. PubMed ID: 18195264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality of Life and Utility Measurement in a Large Clinical Trial Sample of Patients with Mild to Moderate Alzheimer's Disease: Determinants and Level of Changes Observed.
    Lacey L; Bobula J; Rüdell K; Alvir J; Leibman C
    Value Health; 2015 Jul; 18(5):638-45. PubMed ID: 26297092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. APOE genotype, memory test performance, and the risk of Alzheimer's disease in the Canadian Study of Health and Aging.
    Klages JD; Fisk JD; Rockwood K
    Dement Geriatr Cogn Disord; 2003; 15(1):1-5. PubMed ID: 12457072
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.